Osteoporosis a major public health problem of our time, yet we are uncertain of its cause and inadequate in its treatment. We believe that further progress requires a better understanding of the factors and mechanisms regulating bone mass. We have, therefore, designed a center to support five projects that build from basic studies on the biology of bone cells, through animal models to clinical, epidemiological, and therapeutic investigations. Using a new in vitro model, Project 1 will focus on the mode of action and regulation of the osteoclast and the interaction of these cells with others present in the skeleton. Project 2 will probe the interrelationships among the calcium/vitamin D endocrine system, ovarian hormone function and bone loss using a combination of animal models and human studies. In Project 3, we will evaluate the physiological responses to phosphate administration in healthy and osteoporotic subjects and explore the efficacy of phosphate as a skeletal activator. Project 4 will combine an epidemiological approach with a prospective study to identify the factors that are important in the achievement of maximal skeletal mass after cessation of growth. Project 5 will draw together several common themes of the center to address the issue of treatment of established osteoporosis. New knowledge on the effects of phosphate on skeletal metabolism, and altered vitamin D metabolism in osteoporosis will be used to design novel treatment protocols. The rapid emergence of our center as a nationally recognized research group in metabolic bone disease, together with the demographics of the New York Metropolitan area, afford us a unique opportunity for the development of a Specialized Center of Research in Osteoporosis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Specialized Center (P50)
Project #
5P50AR039191-03
Application #
3105171
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Project Start
1987-09-30
Project End
1992-08-31
Budget Start
1989-09-01
Budget End
1990-08-31
Support Year
3
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Helen Hayes Hospital
Department
Type
DUNS #
157119244
City
Menands
State
NY
Country
United States
Zip Code
12204
Ascenzi, Maria-Grazia; Liao, Vivian P; Lee, Brittany M et al. (2012) Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis. J Bone Miner Res 27:702-12
Zhang, Hao; Doty, Stephen B; Hughes, Christine et al. (2007) Increased resorptive activity and accompanying morphological alterations in osteoclasts derived from the oim/oim mouse model of osteogenesis imperfecta. J Cell Biochem 102:1011-20
Dempster, David W; Hughes-Begos, Christine E; Plavetic-Chee, Katarina et al. (2005) Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblasts. J Cell Biochem 95:139-48
Cosman, Felicia; Nieves, Jeri; Zion, Marsha et al. (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353:566-75
Iida-Klein, A; Lu, S Shou; Kapadia, R et al. (2005) Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice. J Endocrinol 186:549-57
Kurland, Etah S; Heller, Samantha L; Diamond, Beverly et al. (2004) The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 15:992-7
Kim, Chi Hyun; Takai, Erica; Zhou, Hua et al. (2003) Trabecular bone response to mechanical and parathyroid hormone stimulation: the role of mechanical microenvironment. J Bone Miner Res 18:2116-25
Rubin, Mishaela R; Bilezikian, John P (2003) New anabolic therapies in osteoporosis. Endocrinol Metab Clin North Am 32:285-307
Zhou, H; Iida-Klein, A; Lu, S S et al. (2003) Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 32:513-20
Dempster, David W (2003) The pathophysiology of bone loss. Clin Geriatr Med 19:259-70, v-vi

Showing the most recent 10 out of 125 publications